pipette
ESEspañol

A PTN-Rich MSC Subtype Promotes Cartilage Repair in End-Stage Knee Osteoarthritis

Z. Wang, L. Yin, F. Zhao, D. Liu, J. Li, J. Chu, Z. Zhou, H. Liu, R. Fan, Z. Yuan, Y. Zhang, L. Liu, G. Yu, M. Sun, B. Shi, J. Han, Y. Zhao

PreprintReal-world use

In the authors' words

Mesenchymal stem cell (MSC) therapy for end-stage knee osteoarthritis (KOA) shows inconsistent efficacy, and whether MSCs retain cartilage repair capacity in the inflammatory joint remains unclear. Using single-cell RNA sequencing of human Kellgren-Lawrence grade (G ) and (G ) KOA joint tissues and exogenous MSCs, we found that pleiotrophin (PTN) signalling shifts from MSC-chondrocyte crosstalk to chondrocyte-dominated autocrine signalling, with PTN exhaustion and elevated cluster of differentiation 74 (CD74) in G cartilage. We therefore identified and sorted a PTN-rich CD74-low placenta-derived MSC subtype and evaluated it in a murine KOA model and in co-culture with patient-derived chondrocytes. This subtype enhanced cartilage repair, upregulated SOX9, and suppressed MMP13, CD74, IL-6, and IL-1{beta}, potentially through CD74 suppression and reduced NF-{kappa}B signaling. These findings provide a basis for functionally defined, stage-matched cell therapy tailored to the pathological microenvironment of end-stage KOA.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, November 10. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.06.764540